• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Tango Therapeutics stock soars on promising pancreatic cancer data

by June 8, 2026
written by June 8, 2026

Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat.

The drug was tested in combination with Revolution Medicines’ daraxonrasib.

The sharp rally pushed the stock toward a record closing high and marked one of its strongest single-day performances in more than a year, as investors responded positively to data that suggested the drug combination could offer a promising new treatment option for pancreatic cancer, one of the deadliest forms of the disease.

The latest results come from an ongoing Phase 1/2 study evaluating vopimetostat alongside daraxonrasib and zoldonrasib in patients with advanced MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma, as well as non-small cell lung cancer.

Pancreatic cancer data exceeds expectations

According to the company, the combination of vopimetostat and daraxonrasib produced a 92% objective response rate in pancreatic cancer patients, meaning tumors shrank or disappeared in 11 out of 12 evaluable participants.

The study also showed a 90% progression-free survival rate after six months and 100% disease control, indicating that nearly all patients experienced either tumor reduction or disease stabilization.

The combination demonstrated additional promise in a small group of non-small cell lung cancer patients, where the company reported a 100% response rate.

A separate treatment arm combining vopimetostat with zoldonrasib generated a 52% objective response rate, a 74% six-month progression-free survival rate, and a 96% disease control rate in pancreatic cancer patients.

Importantly, the company said the treatment combinations were generally well tolerated, with few major side effects reported and no treatment-related Grade 4 or Grade 5 adverse events observed.

“The results from our ongoing combination trial dramatically exceeded our expectations,” Tango Therapeutics CEO Malte Peters said on a conference call Monday.

Peters added that Tango’s “primary focus is now to bring forward” the vopimetostat and daraxonrasib combination “approach in pancreatic cancer.”

The company said the findings support advancing the combination into a larger Phase 3 study as a potential first-line, chemotherapy-free treatment for newly diagnosed pancreatic cancer patients by the end of 2026.

Analysts turn more optimistic

Wall Street analysts responded positively to the data, with several firms raising price targets and reiterating bullish ratings.

Wolfe Research upgraded Tango Therapeutics to “Outperform” from “Peer Perform” and assigned a $35 price target. Analyst Kalpit Patel described the findings as “groundbreaking with no major red flags.”

The firm also increased its estimate for vopimetostat’s unadjusted global peak sales potential to approximately $2.6 billion from $1.9 billion while raising its probability of success.

Mizuho analyst Joseph Catanzaro also maintained an “Outperform” rating and increased his price target to $36 from $30.

Catanzaro said the data “starts to tell a potentially very compelling signal of improved long-term outcomes.”

B. Riley Securities analyst Yuan Zhi also raised his price target to $35 from $21 while maintaining a Buy rating.

Zhi described the 92% objective response rate from the vopimetostat and daraxonrasib combination as “unprecedented.”

He added that the early results leave Tango Therapeutics “undervalued at current levels.”

Focus shifts to late-stage development

While the study remains relatively small and does not include a comparison group, Monday’s update adds to growing industry enthusiasm surrounding daraxonrasib and the broader effort to improve outcomes for pancreatic cancer patients.

Tango also highlighted additional pipeline opportunities, with Peters noting that future data releases involving vopimetostat as a standalone treatment in lung cancer and its TNG456 therapy in glioblastoma represent “significant long-term opportunity” for the company.

The latest findings have strengthened investor confidence that vopimetostat could evolve into a late-stage pancreatic cancer program, particularly as the company prepares for larger clinical trials.

Overall, analysts appear broadly optimistic about Tango’s prospects.

According to FactSet data cited in reports, the company currently carries an average Buy rating among Wall Street firms, with an average price target of approximately $35.09.

As the company moves toward Phase 3 testing, investors will be watching closely to see whether the promising early data can be replicated in larger studies.

The post Tango Therapeutics stock soars on promising pancreatic cancer data appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Dow slips 80 points as chip stocks rebound, ceasefire hopes lift markets
next post
Foreign capital is fleeing South Korean stocks: here’s why you should buy instead

related articles

Anthropic’s ANT closes at $97.17, up 17% on...

November 19, 2026

Evening digest: Anthropic makes historic debut, AMD falls...

November 19, 2026

Nvidia stock falls for sixth day as Anthropic...

November 19, 2026

Aswath Damodaran values Anthropic at $76 a share,...

November 19, 2026

Anthropic pops 34% to cross $2 trillion valuation...

November 19, 2026

Anthropic CEO Dario Amodei defends $900B AI spending...

November 19, 2026

Temu owner just cut its marketing bill: stock...

November 19, 2026

Best Trading Platforms to Buy Anthropic Stock (ANT)

November 19, 2026

AMD stock falls 7% as Hunterbrook alleges links...

November 19, 2026

Anthropic IPO: How much could ANT stock rise...

November 19, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • US, China strike deal to lower tariffs on $30B in goods after Trump-Xi Washington summit

    September 26, 2026
  • Evening digest: Iran war lifts oil, Waymo eyes $3B debt deal

    September 2, 2026
  • ‘Out of control’ killings in Spanberger’s Virginia reach ‘insane’ point as migrant charged in stabbing spree

    September 16, 2026
  • Socialist-backed Michigan Senate hopeful calls American politics a ‘disease’ after professing love for US

    July 21, 2026
  • Trump’s Bedminster turf could make or break his last two years in the White House

    August 24, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Intel, AMD stocks slide again in aftermath of Broadcom’s weak outlook

    June 5, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,663)
  • Stock (90)

Latest Posts

  • Nvidia stock still below $200 mark: what’s behind the recent underperformance?

    June 30, 2026
  • Dow rises 423 points as tech stocks rebound, telecom shares slide on SpaceX

    October 9, 2026
  • Why Oracle stock is declining on Monday?

    November 16, 2026

Recent Posts

  • Visa Q4 profit jumps: can earnings keep pace with the stock?

    October 27, 2026
  • Fetterman refuses to defend Platner, calls him ‘baggage’ as scandals mount

    June 10, 2026
  • Why Samsung, SK Hynix shares rebounded on Wednesday?

    November 18, 2026

Editor’s Pick

  • Republican sounds alarm on rising Dem star: ‘This guy’s going to be a problem’

    September 10, 2026
  • 5 things to know before Wall Street opens on October 30

    October 30, 2026
  • Apple bets boring is better

    June 10, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock